JP2022538690A5 - - Google Patents

Info

Publication number
JP2022538690A5
JP2022538690A5 JP2022500512A JP2022500512A JP2022538690A5 JP 2022538690 A5 JP2022538690 A5 JP 2022538690A5 JP 2022500512 A JP2022500512 A JP 2022500512A JP 2022500512 A JP2022500512 A JP 2022500512A JP 2022538690 A5 JP2022538690 A5 JP 2022538690A5
Authority
JP
Japan
Application number
JP2022500512A
Other languages
Japanese (ja)
Other versions
JPWO2021007160A5 (https=
JP7622031B2 (ja
JP2022538690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040891 external-priority patent/WO2021007160A1/en
Publication of JP2022538690A publication Critical patent/JP2022538690A/ja
Publication of JP2022538690A5 publication Critical patent/JP2022538690A5/ja
Publication of JPWO2021007160A5 publication Critical patent/JPWO2021007160A5/ja
Priority to JP2025005471A priority Critical patent/JP2025063195A/ja
Application granted granted Critical
Publication of JP7622031B2 publication Critical patent/JP7622031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500512A 2019-07-05 2020-07-06 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 Active JP7622031B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005471A JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962871051P 2019-07-05 2019-07-05
US62/871,051 2019-07-05
US202062971196P 2020-02-06 2020-02-06
US62/971,196 2020-02-06
US202062981401P 2020-02-25 2020-02-25
US62/981,401 2020-02-25
PCT/US2020/040891 WO2021007160A1 (en) 2019-07-05 2020-07-06 Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005471A Division JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Publications (4)

Publication Number Publication Date
JP2022538690A JP2022538690A (ja) 2022-09-05
JP2022538690A5 true JP2022538690A5 (https=) 2023-08-03
JPWO2021007160A5 JPWO2021007160A5 (https=) 2023-08-03
JP7622031B2 JP7622031B2 (ja) 2025-01-27

Family

ID=71842858

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500512A Active JP7622031B2 (ja) 2019-07-05 2020-07-06 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
JP2025005471A Pending JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005471A Pending JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Country Status (8)

Country Link
US (1) US20220259254A1 (https=)
EP (1) EP3993834A1 (https=)
JP (2) JP7622031B2 (https=)
CN (1) CN114340680A (https=)
AU (1) AU2020310853A1 (https=)
CA (1) CA3145889A1 (https=)
IL (1) IL289596A (https=)
WO (1) WO2021007160A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4295917A3 (en) * 2020-08-07 2024-02-28 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JP2024542021A (ja) 2021-10-29 2024-11-13 タンボ・インコーポレイテッド ペイロードのin vivo標的化送達用のテトラジンコンジュゲート
EP4704904A1 (en) 2023-05-04 2026-03-11 Tambo, Inc. Tetrazine-based targeting agents for in vivo delivery of a payload
CN121419790A (zh) 2023-05-18 2026-01-27 坦博公司 反式环辛烯修饰的靶向性蛋白质降解剂缀合物
AU2024300552A1 (en) * 2023-07-27 2026-01-29 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025059685A1 (en) 2023-09-15 2025-03-20 Tambo, Inc. Methods for in vivo targeted delivery of a payload
CN117599001B (zh) * 2023-11-29 2025-05-09 南京鼓楼医院 一种生物正交Janus微球及其制备方法和应用
CN118121704B (zh) * 2024-02-29 2024-12-17 中山大学附属第一医院 假体周围感染治疗靶点及其应用
WO2025231424A1 (en) * 2024-05-02 2025-11-06 Arizona Board Of Regents On Behalf Of Arizona State University Procapped mrna for targeted cell translation

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
WO2007119815A1 (ja) 2006-04-14 2007-10-25 Kyowa Hakko Kirin Co., Ltd. Toll様受容体9作動薬
KR20100053598A (ko) 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Tlr9의 신규한 합성 효능제
US20110293565A1 (en) 2009-01-30 2011-12-01 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
JP5951615B2 (ja) * 2010-10-01 2016-07-13 ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. Tlrアゴニストの治療用途および組み合わせ治療
US20150297741A1 (en) * 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10130711B2 (en) 2013-06-19 2018-11-20 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
ES2880468T3 (es) 2014-03-14 2021-11-24 Univ California Conjugados de TCO y métodos para el suministro de agentes terapéuticos
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
PE20170198A1 (es) 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
CN107708706A (zh) 2015-05-29 2018-02-16 戴纳瓦克斯技术公司 用于治疗肺的癌症的多核苷酸Toll样受体9激动剂的肺内施用
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドVerastem,Inc. 治療用組成物、組合せ物および使用の方法
CR20180101A (es) 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
JP6823067B2 (ja) 2015-09-10 2021-01-27 タンボ・インコーポレイテッド 生体直交型組成物
CA3002236A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
RS67188B1 (sr) 2016-01-11 2025-10-31 Innate Tumor Immunity Inc Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11033569B2 (en) 2016-07-06 2021-06-15 Sperovie Biosciences, Inc. Compounds,Compositions, and methods for the treatment of disease
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
MX2019000660A (es) 2016-07-15 2019-10-02 Sperovie Biosciences Inc Compuestos, composiciones y métodos para el tratamiento de enfermedades.
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
US10414747B2 (en) 2016-10-04 2019-09-17 Merck Sharp & Dohme Corp. Benzo[b]thiophene compounds as sting agonists
JP7265989B2 (ja) 2016-10-25 2023-04-27 ウロゲン ファーマ リミテッド 体腔の免疫調節治療
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
WO2018118665A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
CA3047394A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
US11492367B2 (en) 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
ES2983582T3 (es) 2017-04-07 2024-10-23 Tambo Inc Composiciones bioortogonales
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
PE20200696A1 (es) 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドCuradev Pharma Limited ヒトstingの複素環式小分子調節因子
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
JP7270608B2 (ja) 2017-08-31 2023-05-10 エフ-スター・セラピューティクス・インコーポレイテッド 化合物、組成物、及び疾患の治療方法
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
MX2020004600A (es) 2017-11-02 2020-10-05 Janssen Biopharma Inc Constructos de oligonucleotidos y usos de estos.
JP7195317B2 (ja) 2017-11-10 2022-12-23 武田薬品工業株式会社 Sting調節剤化合物、ならびに製造及び使用する方法
WO2019118839A1 (en) 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
KR20200099556A (ko) 2017-12-15 2020-08-24 바이엘 애니멀 헬스 게엠베하 면역자극성 조성물
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
US20190185509A1 (en) 2017-12-20 2019-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2022538690A5 (https=)
BR112021014123A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015220A2 (https=)
BR102021015247A2 (https=)